The US Food and Drug Administration has awarded Priority Review to a submission from Spanish drugmaker PharmaMar (MC: PHM) and Jazz Pharmaceuticals (Nasdaq: JAZZ) for lurbinectedin.
Towards the end of 2019, PharmaMar agreed a deal with Ireland-incorporated Jazz Pharma for lurbinectedin in the USA.
That agreement, worth up to a billion dollars for PharmaMar, was reached shortly after the firm submitted its application to the US regulator, for the treatment of people with relapsed small-cell lung cancer (SCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze